WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010027513) METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/027513    International Application No.:    PCT/US2009/005064
Publication Date: 11.03.2010 International Filing Date: 08.09.2009
IPC:
A61K 47/48 (2006.01), A61P 35/00 (2006.01)
Applicants: PSMA DEVELOPMENT COMPANY, LLC [US/US]; 777 Old Saw Mill River Road Tarrytown, NY 10591 (US) (For All Designated States Except US).
MA, Dangshe [US/US]; (US) (For US Only).
OLSON, William C. [US/US]; (US) (For US Only).
MORRIS, Stephen [US/US]; (US) (For US Only).
ISRAEL, Robert [US/US]; (US) (For US Only)
Inventors: MA, Dangshe; (US).
OLSON, William C.; (US).
MORRIS, Stephen; (US).
ISRAEL, Robert; (US)
Agent: VATLAND, Janice, A.; Wolf, Greenfield & Sacks, P.C. Federal Reserve Plaza 600 Atlantic Avenue Boston, MA 02210-2206 (US)
Priority Data:
61/205,395 20.01.2009 US
61/095,300 08.09.2008 US
Title (EN) METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS
(FR) PROCÉDÉS POUR TUER DES CELLULES CANCÉREUSES EXPRIMANT PSMA ET RÉSISTANTES AU TAXANE
Abstract: front page image
(EN)Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane- resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted with an antibody-drug conjugate (ADC) that comprises an antibody or antigen-binding fragment thereof that specifically binds to PSMA conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine.
(FR)L'invention concerne des procédés pour tuer des cellules cancéreuses exprimant l'antigène membranaire spécifique prostatique (PSMA) et résistantes au taxane. En particulier, les cellules cancéreuses exprimant PSMA et résistantes au taxane sont mises en contact avec un conjugué anticorps-médicament (ADC) qui comprend un anticorps ou l'un de ses fragments liant l'antigène qui se lie spécifiquement au PSMA conjugué à la monométhylauristatine noréphédrine ou à la monométhylauristatine phénylalanine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)